Mutual of America Capital Management LLC Sells 3,603 Shares of Repligen Corporation $RGEN

Mutual of America Capital Management LLC cut its position in Repligen Corporation (NASDAQ:RGEN) by 12.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 25,568 shares of the biotechnology company’s stock after selling 3,603 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Repligen were worth $3,418,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Teacher Retirement System of Texas increased its position in shares of Repligen by 8.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 17,092 shares of the biotechnology company’s stock valued at $2,285,000 after buying an additional 1,382 shares in the last quarter. Slow Capital Inc. grew its stake in Repligen by 23.9% in the third quarter. Slow Capital Inc. now owns 44,076 shares of the biotechnology company’s stock valued at $5,892,000 after acquiring an additional 8,511 shares during the period. Verdence Capital Advisors LLC increased its holdings in shares of Repligen by 4.6% in the third quarter. Verdence Capital Advisors LLC now owns 4,910 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 215 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Repligen by 1.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 75 shares during the period. Finally, Amalgamated Bank lifted its holdings in shares of Repligen by 0.6% during the 3rd quarter. Amalgamated Bank now owns 24,285 shares of the biotechnology company’s stock valued at $3,246,000 after purchasing an additional 143 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN opened at $149.37 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $175.77. The firm has a market cap of $8.41 billion, a P/E ratio of 7,472.24, a price-to-earnings-growth ratio of 2.84 and a beta of 1.12. The business’s fifty day moving average is $164.37 and its 200-day moving average is $143.89.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The firm’s quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.43 EPS. Sell-side analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony Hunt sold 25,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the completion of the transaction, the director directly owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. The trade was a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 49,657 shares of company stock worth $7,721,077 over the last 90 days. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on RGEN shares. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Evercore ISI upped their target price on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Canaccord Genuity Group increased their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $179.62.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.